This study examined the role of TIF1γ (Transcriptional Intermediary Factor 1-γ) in maintaining the stability of regulatory T (Treg) cells during inflammation, including autoimmune settings and helminth infection, using TIF1γ-deficient Treg cell models.
TIF1γ-deficient Treg cells lost Foxp3 expression and were reprogrammed into pro-inflammatory effector states (Th1-like or Th2-like) in a cell-intrinsic manner; this instability was driven by β-catenin/TCF7 pathway activation rather than disrupted TGFβ signaling. Genetic or pharmacological targeting of β-catenin restored Treg stability and function.
Findings are based on mouse models of Treg-specific TIF1γ deficiency; translation to human Treg biology and clinical relevance is not established. The full paper text provided consists largely of supplementary materials and antibody tables, limiting assessment of full mechanistic detail and statistical rigor.
TIF1γ-β-catenin signaling is a potential therapeutic target for diseases driven by Treg instability, such as autoimmunity. Pharmacological inhibition of β-catenin may offer a strategy to stabilize Treg identity in inflammatory conditions.